Related Experiment Video
Updated: Mar 14, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins
1Department of Oncology, Division of Medical Oncology, Juravinski Cancer Centre, 699 Concession Street, Hamilton, Ontario, L8V 5C2, Canada.
Abstract:
Despite the significant survival benefit of taxane therapy in metastatic castration-resistant prostate cancer (mCRPC), all patients inevitably develop treatment resistance. An understanding of resistance mechanisms has led to new therapies for prostate cancer (cabazitaxel, abiraterone and enzalutamide), all of which have improved survival following first-line docetaxel. Another treatment, currently in development, targets the prosurvival molecule clusterin. Custirsen, an antisense molecule that inhibits clusterin production, has shown promise in combination with docetaxel in mCRPC patients at risk for poor outcomes. Although optimal sequence and combination of available therapies is unclear, the heterogeneity of mCRPC suggests a continuing need for personalized treatment regimens and improved abilities to predict which patients will respond to the available treatment options.
Insights
Metastatic castration-resistant prostate cancer (mCRPC) inevitably develops resistance to taxane therapy. New treatments targeting clusterin, like custirsen, show promise for improving outcomes in mCRPC patients.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Taxane therapy offers survival benefits for metastatic castration-resistant prostate cancer (mCRPC) but is eventually overcome by treatment resistance.
- Emerging therapies, including cabazitaxel, abiraterone, and enzalutamide, have improved survival post-first-line docetaxel.
- Understanding resistance mechanisms is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To evaluate the potential of custirsen, an antisense molecule targeting clusterin, in combination with docetaxel for mCRPC patients.
- To explore new treatment options for patients with metastatic castration-resistant prostate cancer who are at risk for poor outcomes.
Main Methods:
- Investigated custirsen, an antisense molecule designed to inhibit clusterin production.
- Assessed the efficacy of custirsen in combination with docetaxel in a patient population with mCRPC.
Main Results:
- Custirsen in combination with docetaxel demonstrated promise in mCRPC patients.
- The study highlighted potential benefits for patients with poor prognostic indicators.
Conclusions:
- While optimal sequencing of therapies for mCRPC remains unclear, custirsen represents a promising addition to the treatment landscape.
- The heterogeneity of mCRPC necessitates personalized treatment approaches and better predictive biomarkers for treatment response.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:15Drugs that Stabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...